Encysive Pharmaceuticals (ENCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Encysive Pharmaceuticals (ENCY)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: IRWIN JAMES FRANKEL	6/11/2007 8:24:54 AM
	Read Replies (1) of 205

ENCY Encysive Pharma: Dawson James cautiously optimistic for Friday PDUFA date for Thelin (4.42 ) Dawson James believes that ENCY has been caught up in the FDA's continuing negative publicity surrounding drug safety. Firm continues to believe the Thelin's known interaction with coumadin, which all of their experts in the U.S. and Europe agreed was easily manageable, is the FDA sticking point. Firm notes Thelin approvals in 6 countries plus the recent FDA lifting the clinical hold on ENCY's 2nd-generation Thelin drug, TBC3711, to re-commence clinical trials, makes them cautiously optimistic for FDA approval by Friday.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next